Advertisement

Product › Details
Jakavi®
![]() |
Next higher product group | ruxolitinib (INC424) |
![]() |
Status | 2012-08-28 registration start |
Annual sales | USD 777,000,000 (sales (2017) 2017) | |
![]() |
Organisation | Novartis AG (NYSE: NVS) |
Group | Novartis (Group) | |
Record changed: 2023-07-10 |
Advertisement

More documents for anti-inflammatory drug
- [1] Windward Bio AG. (1/10/25). "Press Release: Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD". Basel....
- [2] Kynos Therapeutics Ltd.. (10/29/24). "Press Release: Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio". Freiburg....
- [3] 65LAB. (7/29/24). "Press Release: 65LAB and Duke-NUS Award US$1.85 Million to Combat Chronic Inflammation". Singapore....
- [4] Scinai Immunotherapeutics Ltd.. (9/15/23). "Press Release: Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering". Jerusalem....
- [5] Scinai Immunotherapeutics Ltd.. (9/6/23). "Press Release: BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics". Jerusalem....
- [6] Upstream Bio (US). (6/20/23). "Press Release: Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases". Allschwil....
- [7] BiondVax Pharmaceuticals Ltd.. (6/5/23). "Press Release: BiondVax Signs Exclusive License Agreement for Development and Commercialization of a Novel anti-IL-17 Antibody". Jerusalem....
- [8] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Public Offering of Ordinary Shares". Jena....
- [9] Amgen Inc.. (8/4/22). "Press Release: Amgen to Acquire ChemoCentryx for $4 Billion in Cash". Thousand Oaks, CA & San Carlos, CA....
- [10] Upstream Bio (US). (6/2/22). "Press Release: Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases". Waltham, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top